Aug 26- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck& Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer.» Read More
U.S. scientists face legal obstacles and frustrations in trying to study the medical uses of marijuana, the New York Times reports.
All three U.S. laboratories established to fight major public health threats say they are standing by to scale up a treatment for Ebola.
Pfizer confronts surge of lawsuits over Lipitor. Pharmaceutical giant Pfizer is facing a mounting number of lawsuits by women who say the company knew its blockbuster anti-cholesterol drug Lipitor was linked to a small increased risk of type-2 diabetes but never properly warned the public.
Tekmira Pharmaceutical's stocks have soared since the U.S. Food and Drug Administration cleared its experimental Ebola drug for human use.
Pfizer is facing a mounting wave of lawsuits by women who allege that the company knew about possible serious side effects of its drug Lipitor.
Aug 8- Pharmaceutical giant Pfizer is facing a mounting wave of lawsuits by women who allege that the company knew about possible serious side effects of its blockbuster anti-cholesterol drug Lipitor but never properly warned the public.
British investigator Peter Humphrey and his wife stand trial in Shanghai on charges of illegally obtaining information. CNBC's Eunice Yoon reports.
It's unlikely but not outside the realm of possibility that those infected with Ebola will come to the U.S., the CDC's Beth Bell said.
Dr. Beth Bell, CDC Infectious Diseases Center, discusses the Ebola crisis in West Africa, and the risks to U.S. citizens. Bell explains current experimental treatments.
The CDC Director is testifying before Congress on Ebola, and pharma companies are scrambling to create drugs to help. CNBC's Meg Tirrell, and Michael Yee, RBC Capital Markets, discuss some of these companies.
*Cuts top end of FY earnings forecast to $3.45/ shr from $3.60/ shr. Aug 7- Mylan Inc shaved the top end of its full-year revenue and earnings forecasts, citing delays in approval from the U.S. Food and Drug Administration for key generic drugs that it plans to launch this year.
Aug 7- Specialty drugmaker Mallinckrodt Plc reported a smaller quarterly loss and raised its full-year profit and revenue forecast, citing strong sales of its recently acquired pain drug Ofirmev.
Aug 7- Generic drug maker Mylan Inc narrowed its full-year revenue and earnings forecast, citing delays in U.S. Food and Drug Administration approval of key products. The company narrowed its revenue forecast range to $7.8 billion- $8 billion from $7.8 billion- $8.2 billion.
Aug 7- Drugmaker Auxilium Pharmaceuticals posted a much bigger-than-expected quarterly loss, hurt by falling sales of testosterone gel Testim. Auxilium lost $36.5 million, or 73 cents per share, in the second quarter ended June 30, compared with a net profit of $42.7 million, or 86 cents per share, a year earlier. Excluding items, the loss was 44 cents per share.
An experimental treatment for the Ebola virus is rooted in a therapy devised more than 100 years ago—serum. NBC News reports.
U.S. giant Walgreens is expected to buy the remaining stake in the U.K.'s Alliance Boots, but the deal is unlikely to include plans for tax inversion, CNBC's Catherine Boyle reports.
NEW YORK, Aug 6- Drugmakers' use of the tobacco plant as a fast and cheap way to produce novel biotechnology treatments is gaining global attention because of its role in an experimental Ebola therapy.
NEW YORK, Aug 5- Belgian pharmaceutical company UCB is exploring a sale of its Kremers Urban Pharmaceuticals Inc division, a U.S. specialty generics business that could fetch as much as $2 billion, according to people familiar with the matter. Other companies that are exploring similar sales include GlaxoSmithKline Plc, Sanofi SA and Merck& Co Inc..
Aug 5- Generic drug maker Actavis Plc's full-year profit forecast missed analysts' estimates, sending its shares down about 3 percent in premarket trading. Actavis said it expects profit of $13.02- $13.32 per share for the year ending x, below Wall Street estimates of $13.73 per share. Excluding items, Actavis earned $3.42 per share in the second quarter.
Scott Gottlieb, M.D., American Enterprise Institute, and Jeff Allen, Friends of Cancer Research executive director, discuss the FDA's drug approval process and the need in some cases to allow access to experimental therapies.